PE20000338A1 - Formulaciones para la proteccion de conjugados de peg-interferon alfa - Google Patents

Formulaciones para la proteccion de conjugados de peg-interferon alfa

Info

Publication number
PE20000338A1
PE20000338A1 PE1999000243A PE00024399A PE20000338A1 PE 20000338 A1 PE20000338 A1 PE 20000338A1 PE 1999000243 A PE1999000243 A PE 1999000243A PE 00024399 A PE00024399 A PE 00024399A PE 20000338 A1 PE20000338 A1 PE 20000338A1
Authority
PE
Peru
Prior art keywords
interferon alpha
peg
molecules
conjugates
interferon
Prior art date
Application number
PE1999000243A
Other languages
English (en)
Inventor
Douglas Kline
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21957085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20000338(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20000338A1 publication Critical patent/PE20000338A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UNA FORMULACION QUE PREVIENE EL DANO DE CONJUGADOS DE PEG-INTERFERON ALFA DURANTE Y DESPUES DEL PROCESO DE LIOFILIZACION QUE COMPRENDE: a)CONJUGADOS DE PEG-INTERFERON ALFA QUE PUEDEN SER MOLECULAS PEG SIMPLES CONJUGADAS CON MOLECULAS DE INTERFERON ALFA SIMPLES, LAS MOLECULAS DE INTERFERON ALFA PUEDEN SER INTERFERON ALFA-2a, INTERFERON ALFA 2b, INTERFERON ALFA 2c, INTERFERON DE CONSENSO UTILIZANDOSE DE 0,03 mg/ml A 2,0 mg/ml; EL POLIETILENGLICOL ES PEG12000; ESTANDO UNIDO DICHO CONJUGADO A TRAVES DE UN ENLACE DE URETANO O LIGADA EN UN RESIDUO DE HISTIDINA; b)BUFFER COMO FOSFATO DE SODIO DIBASICO ANHIDRO, FOSFATO DE SODIO MONOBASICO DIHIDRATO UTILIZANDOSE DE 0,005 M A 0,1 M; c)UN ESTABILIZANTE COMO DERIVADO DE POLI(OXI-1,2-ETANODIILO); UTILIZANDOSE DE 0,01 mg/ml A 1,0 mg/ml; d)CRIOPROTECTOR COMO SACAROSA UTILIZANDOSE 20 mg/ml A 100 mg/ml; e)SOLVENTE COMO AGUA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE LIOFILIZACION OBTENIENDOSE UN POLVO LIOFILIZADO QUE COMPRENDE 0,08% DE CONJUGADOS DE PEG-INTERFERON ALFA; 3,6% DE FOSFATO DE SODIO; 0,12% DE DERIVADO DE POLI(OXI-1,2-ETANODIILO); 96,2% DE SACAROSA. EL INTERFERON ALFA 2b PUEDE SER UTIL PARA EL TRATAMIENTO DE CARCINOMA DE CELULAS RENALES, CARCINOMA DE KAPOSI RELACIONADO CON EL SIDA, HEPATITIS B CRONICA Y AGUDA, HEPATITIS CRONICA Y AGUDA NO A, NO B, C Y HEPATITIS C
PE1999000243A 1998-03-26 1999-03-25 Formulaciones para la proteccion de conjugados de peg-interferon alfa PE20000338A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4890798A 1998-03-26 1998-03-26

Publications (1)

Publication Number Publication Date
PE20000338A1 true PE20000338A1 (es) 2000-05-16

Family

ID=21957085

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000243A PE20000338A1 (es) 1998-03-26 1999-03-25 Formulaciones para la proteccion de conjugados de peg-interferon alfa

Country Status (26)

Country Link
EP (1) EP1066059B1 (es)
JP (3) JP3643034B2 (es)
KR (1) KR100420642B1 (es)
CN (1) CN1191863C (es)
AR (1) AR014772A1 (es)
AT (1) ATE297761T1 (es)
AU (1) AU754002B2 (es)
BR (1) BR9909087A (es)
CA (1) CA2324467C (es)
CO (1) CO5080738A1 (es)
CZ (1) CZ302005B6 (es)
DE (1) DE69925820T2 (es)
ES (1) ES2241272T3 (es)
HK (1) HK1029754A1 (es)
HU (1) HU228877B1 (es)
ID (1) ID28470A (es)
IL (2) IL138221A0 (es)
MY (1) MY119227A (es)
NO (1) NO329916B1 (es)
NZ (1) NZ506631A (es)
PE (1) PE20000338A1 (es)
PL (1) PL193286B1 (es)
PT (1) PT1066059E (es)
SK (1) SK285284B6 (es)
TW (2) TWI243057B (es)
WO (1) WO1999048535A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1066059B1 (en) * 1998-03-26 2005-06-15 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
JP4721488B2 (ja) * 1999-04-08 2011-07-13 シェーリング コーポレイション 腎細胞ガン処置
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US20020009428A1 (en) * 2000-01-24 2002-01-24 Zaknoen Sara L. Combination therapy for cancer
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 ｐｅｇ의결합체 제조방법
KR100777195B1 (ko) 2000-04-03 2007-11-19 산텐 세이야꾸 가부시키가이샤 송달성 물질 및 이를 이용한 약물 송달 시스템
DK1478339T3 (da) 2002-02-22 2008-08-25 Schering Corp Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
DE602005022895D1 (de) * 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
WO2009080699A2 (en) 2007-12-20 2009-07-02 Merck Serono S.A. Peg-interferon-beta formulations
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
JP2015535238A (ja) * 2012-10-26 2015-12-10 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ ペグインターフェロンα−２ｂの安定な医薬組成物
KR101736870B1 (ko) 2014-08-20 2017-05-18 한국코러스 주식회사 인터페론 접합체를 포함하는 복합체 및 이의 제조방법
EP3463308B1 (en) 2016-06-01 2021-12-01 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN112358541B (zh) * 2020-11-25 2022-04-01 广州迪澳医疗科技有限公司 一种重组人γ-干扰素的冻干保护剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
DK0730470T3 (da) * 1993-11-10 2002-06-03 Enzon Inc Forbedrede interferonpolymerkonjugater
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
JP2000507917A (ja) * 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP1066059B1 (en) * 1998-03-26 2005-06-15 Schering Corporation Formulations for protection of peg-interferon alpha conjugates

Also Published As

Publication number Publication date
HU228877B1 (en) 2013-06-28
DE69925820D1 (de) 2005-07-21
WO1999048535A1 (en) 1999-09-30
JP2005104985A (ja) 2005-04-21
IL138221A (en) 2007-12-03
CA2324467C (en) 2002-11-05
KR100420642B1 (ko) 2004-03-02
BR9909087A (pt) 2000-12-05
AR014772A1 (es) 2001-03-28
AU754002B2 (en) 2002-10-31
PL345568A1 (en) 2001-12-17
AU3181299A (en) 1999-10-18
CZ302005B6 (cs) 2010-09-01
MY119227A (en) 2005-04-30
JP2003221345A (ja) 2003-08-05
KR20010034654A (ko) 2001-04-25
HUP0101749A3 (en) 2001-12-28
PT1066059E (pt) 2005-10-31
NO20004785L (no) 2000-09-25
JP4580744B2 (ja) 2010-11-17
SK285284B6 (sk) 2006-10-05
SK14262000A3 (sk) 2001-04-09
HK1029754A1 (en) 2001-04-12
ES2241272T3 (es) 2005-10-16
NZ506631A (en) 2003-03-28
DE69925820T2 (de) 2006-05-18
CN1295484A (zh) 2001-05-16
NO329916B1 (no) 2011-01-24
CA2324467A1 (en) 1999-09-30
ID28470A (id) 2001-05-24
IL138221A0 (en) 2001-10-31
TWI250024B (en) 2006-03-01
NO20004785D0 (no) 2000-09-25
PL193286B1 (pl) 2007-01-31
JP2002507583A (ja) 2002-03-12
CN1191863C (zh) 2005-03-09
EP1066059B1 (en) 2005-06-15
TW200536557A (en) 2005-11-16
EP1066059A1 (en) 2001-01-10
TWI243057B (en) 2005-11-11
JP3643034B2 (ja) 2005-04-27
HUP0101749A2 (hu) 2001-11-28
CO5080738A1 (es) 2001-09-25
CZ20003315A3 (cs) 2001-04-11
ATE297761T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
PE20000338A1 (es) Formulaciones para la proteccion de conjugados de peg-interferon alfa
ATE294571T1 (de) Echinocandin pharmazeutische zusammensetzungen
NO175704C (no) Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon
EA200400242A1 (ru) Фармацевтические композиции, содержащие бета-лапахон или его производные или аналоги, и способы их применения
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
DK97987A (da) Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation
DK1223990T3 (da) Formuleringer af hyaluronsyre til tilförsel af osteogene proteiner
SE7901683L (sv) Nya resorberbara galeniska kompositioner
ECSP045496A (es) "preparaciones acidas de insulina con estabilidad mejorada"
FI933740A0 (fi) Peg-interferonkonjugat
DE69939036D1 (de) PEG Konjugate von LHRH Analogen
AR008927A1 (es) Una composicion farmaceutica que comprende una sustancia medicinalmente activa insoluble en agua con propiedades mejoradas de disolucion, absorcion, etc., y el procedimiento para prepararla
DE69521693T2 (de) Taxanderivate enthaltende arzneizubereitungen
ATE156019T1 (de) Lipophile zusammensetzungen von oligosaccharid- antibiotikasalzen
ES2365832T3 (es) Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
JP2012250995A (ja) Ｐｅｇ−インターフェロンアルファ接合体の配合物
DE69008513T2 (de) Pharmazeutische formulierung von plasminogenaktivatorproteinen.
DK1502586T3 (da) Anvendelse af desinficerende midler ved fremstillingen af en farmaceutisk sammensætning til forebyggelsen eller behandlingen af inflammationer i det indre af menneskekroppen
BR9809708A (pt) Composições farmacêuticas de peptìdeos tendo solubilidade baixa em meio fisiológico
ATE549036T1 (de) Thymosin-alpha-1-peptid/polymer-konjugate
KR900700124A (ko) 흑색종 치료용 il-2 및 dtic의 치료 조성물
MX9207344A (es) Formulaciones mejoradas que tienen mejoradores hidrofobicos de penetracion transdermica y metodo para proveerla.
AR014884A1 (es) Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica
ATE2746T1 (de) Piperidinderivate von 4,5-dialkyl-3-hydroxypyrrol-2-carbons[ureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
BR0009778A (pt) Composições antifúngicas de pseudomicina e métodos para utilização das mesmas

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term